$81.86 +0.84 (1.04%) Biomarin Pharmaceutical Inc - NASDAQ

Dec. 8, 2016 | 10:20 AM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 81.86
Trade Time: Dec 08 10:20 AM Eastern Daylight Time
Change: +0.84 (1.04%)
Prev Close: 81.02
Open: 81.70
Bid: 81.83
Ask: 81.91
  1. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech?

    TalkMarkets | Nov. 23, 2016 | 00:13AM EST
  2. Stock Exchange: Is Technical Analysis Effective Post-Election?

    TalkMarkets | Nov. 10, 2016 | 22:46PM EST
  3. Biogen Upgraded To Overweight From Neutral At Piper Jaffray

    TalkMarkets | Nov. 7, 2016 | 08:08AM EST
  4. Weighing the Week Ahead: Time for Some Clarity?

    TalkMarkets | Nov. 6, 2016 | 01:03AM EST
  5. Stock Exchange: Contrarian Pre-Election Trade Ideas In Chips, Biotech, Trucking, And Energy

    TalkMarkets | Nov. 4, 2016 | 08:53AM EST
  6. Contrarian Pre-Election Trade Ideas In Chips, Biotech, Trucking, And Energy

    TalkMarkets | Nov. 4, 2016 | 08:53AM EST
  7. Seattle Genetics (SGEN) Loss Narrower Than Expected In Q3

    TalkMarkets | Oct. 29, 2016 | 19:13PM EST
  8. J&J Outshines in Q3 Earnings on Strong Pharma Sales

    TalkMarkets | Oct. 18, 2016 | 11:01AM EST
  9. Swing Trading Watch List - October 11, 2016

    TalkMarkets | Oct. 11, 2016 | 22:19PM EST
  10. Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD

    IBD | Jul. 14, 2016 | 10:13AM EST
  11. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus | Jul. 11, 2016 | 12:24PM EST
  12. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug

    Benzinga | Jan. 21, 2016 | 11:23AM EST
  13. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD | Jan. 15, 2016 | 12:53PM EST
  14. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD | Jan. 14, 2016 | 12:29PM EST
  15. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial

    Benzinga | Jan. 11, 2016 | 11:35AM EST
Trading Center